Cargando…
Mild COVID‐19 infection in a group of teriflunomide‐treated patients with multiple sclerosis
Autores principales: | Mantero, Vittorio, Baroncini, Damiano, Balgera, Roberto, Guaschino, Clara, Basilico, Paola, Annovazzi, Pietro, Zaffaroni, Mauro, Salmaggi, Andrea, Cordano, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457441/ https://www.ncbi.nlm.nih.gov/pubmed/32865629 http://dx.doi.org/10.1007/s00415-020-10196-9 |
Ejemplares similares
-
COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis
por: Mantero, Vittorio, et al.
Publicado: (2020) -
Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients
por: Mantero, Vittorio, et al.
Publicado: (2020) -
Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?
por: Mantero, Vittorio, et al.
Publicado: (2020) -
Clinical Application of 2017 McDonald Diagnostic Criteria for Multiple Sclerosis
por: Mantero, Vittorio, et al.
Publicado: (2018) -
Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing–remitting multiple sclerosis in Italy
por: Lazzaro, Carlo, et al.
Publicado: (2022)